Stay updated with breaking news from Tropism Redirection. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BASEL (dpa-AFX) - Voyager Therapeutics, Inc. (VYGR), a developer of adeno-associated virus or AAV capsids, announced Tuesday a license option agreement, under which Novartis (NVS) will receive
Novartis and Voyager Therapeutics announce partnership to develop gene therapies for neurological disorders - News - PharmaTimes
Under the terms of the agreement, Pfizer will have the right to evaluate novel capsids selected for central nervous system and cardiac tropisms from Voyager's TRACER platform and to exercise options...
On October 6, 2021, Voyager Therapeutics and Pfizer entered into a license option agreement, which allows Pfizer to exercise options to license Voyager’s adeno-associated virus (AAV)...
Voyager Therapeutics, Inc (NASDAQ: VYGR) CEO and President Andre Turenne will step down as the beleaguered company announced it would move ...